The association between primary Sjogren's syndrome and non-Hodgkin's lymphoma: a systematic review and meta-analysis of cohort studies.

Diffuse small cleaved cell lymphoma Lymphoma, Non-Hodgkin Sicca syndrome Sjogren’s syndrome

Journal

Clinical rheumatology

ISSN: 1434-9949

Titre abrégé: Clin Rheumatol

Pays: Germany

ID NLM: 8211469

Informations de publication

Date de publication:
09 May 2024

Historique:

received: 28 02 2024

accepted: 02 05 2024

revised: 30 04 2024

medline: 9 5 2024

pubmed: 9 5 2024

entrez: 9 5 2024

Statut: aheadofprint

Résumé

Primary Sjögren's syndrome (pSS), a chronic autoimmune condition, has been associated with an increased risk of several cancers. This study aims to delve into the relationship between pSS and the potential development of non-Hodgkin's lymphoma (NHL) utilizing an in-depth systematic review and meta-analysis approach. To thoroughly explore the topic, we conducted a thorough examination of the literature, drawing from reputable databases such as ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar. Our data collection spanned until February 8, 2024, with no time limitation. Data were analyzed with Stata 14 software at a significance threshold of p < 0.05. We examined 15 cohort studies encompassing a total of 50,308 individuals from 1997 to 2023. The findings revealed a substantial link between pSS and the risk of NHL, evident across all demographics. Specifically, the standardized incidence ratio (SIR) was generally 8.78 (95% CI 5.51, 13.99), with similar trends observed in both men (SIR, 6.29; 95% CI 1.93, 20.51) and women (SIR, 9.60; 95% CI 5.89, 15.63). Additionally, the SIR (10.50 (95% CI 7, 15.75)), HR (2.82 (95% CI 1.28, 6.18)), and OR (10.50 (95% CI 3.04, 36.28)) indices further supported this association. Furthermore, the risk of non-NHL associated with pSS was noticeable across different age groups of 40-49 years (SIR, 30.13; 95% CI 14.62, 62.08), 50-59 years (SIR, 9.12; 95% CI 5.13, 16.19), and 60-69 years (SIR, 9; 95% CI 4.68, 17.32). pSS substantively augments the likelihood of NHL manifestation. It notably impacts females and those in earlier stages of adulthood with more acuity than males and older cohorts.

Identifiants

DOI: 10.1007/s10067-024-06993-6 PMID: 38722505

pubmed: 38722505

doi: 10.1007/s10067-024-06993-6

pii: 10.1007/s10067-024-06993-6

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Duan W, Jiang F, Ouyang S, Yin W, Zeng Q, Yang H (2023) Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study. Front Neurol 14:1212868

pubmed: 37441608 pmcid: 10335809

Luo W, Tian L, Tan B, Shen Z, Xiao M, Wu S et al (2022) Update: innate lymphoid cells in inflammatory bowel disease. Dig Dis Sci 67(1):56–66

pubmed: 33609209

Rajaei E, Jalali MT, Pezeshki SMS, Rezaeeyan H, Maniati M, Elyasi M et al (2020) Dose HLA-B5, 7, 8, 27, and 51 antigens associated to behcet’s disease? A study in Southwestern Iran. Curr Rheumatol Rev 16(2):120–124

pubmed: 31533601

Rajaei E, Shahbazian N, Rezaeeyan H, Mohammadi AK, Hesam S, Zayeri ZD (2019) The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014. Clin Rheumatol 38:3211–3215

pubmed: 31352646

Narvaez J, Sanchez-Fernandez SA, Seoane-Mato D, Diaz-Gonzalez F, Bustabad S (2020) Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases. Sci Rep 10(1):10627

pubmed: 32606345 pmcid: 7327007

Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X et al (2016) Sjögren syndrome. Nat Rev Dis Primers 2(1):1–20

Leone M, Alunno A, Cafaro G, Valentini V, Marcucci E, Bartoloni E et al (2017) The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands. Reumatismo 69(3):93–100

pubmed: 28933131

Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 9(9):544–556

pubmed: 23857130

Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F et al (2015) Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1983–1989

pubmed: 24938285

Mariette X, Criswell L (2018) Primary Sjögren’s syndrome. N Engl J Med 378(10):931–939

pubmed: 29514034

Patel R, Shahane A (2014) The epidemiology of Sjögren’s syndrome. Clin Epidemiol 6:247–255

pubmed: 25114590 pmcid: 4122257

Theander E, Manthorpe R, Jacobsson L (2004) Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 50(4):1262–1269

pubmed: 15077310

Retamozo S, Gheitasi H, Quartuccio L, Kostov B, Corazza L, Bové A et al (2016) Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford) 55(8):1443–1451

pubmed: 27107430

Shahjahani M, Abroun A, Saki N, Bagher Mohammadi SM, Rezaeeyan H (2020) STAT5: from pathogenesis mechanism to therapeutic approach in acute leukemia. Lab Med 51(4):345–351

pubmed: 31860086

Zintzaras E, Voulgarelis M, Moutsopoulos H (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344

pubmed: 16287762

Pan L, Feng F, Wu J, Fan S, Han J, Wang S et al (2022) Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res 181:106270

pubmed: 35605812

Tabatabaee S, Bahrami F, Janahmadi M (2021) The critical modulatory role of spiny stellate cells in seizure onset based on dynamic analysis of a neural mass model. Front Neurosci 15:743720

pubmed: 35002598 pmcid: 8739215

Shen W, Pei P, Zhang C, Li J, Han X, Liu T et al (2023) A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano 17(23):23998–24011

pubmed: 37988029

Tian Z, Zhang Y, Zheng Z, Zhang M, Zhang T, Jin J et al (2022) Gut microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation. Cell host & microbe 30(10):1450–63.e8

Wu W, Li H, Wang Z, Dai Z, Liang X, Luo P et al (2024) The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma. Heliyon 10(1):e23915

pubmed: 38205335

Huang R, Li Y, Wu H, Liu B, Zhang X, Zhang Z (2023) 68Ga-PSMA-11 PET/CT versus 68Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis. Front Oncol 13:1216894. https://doi.org/10.3389/fonc.2023.1216894

Gan Y, Li L, Zhang L, Yan S, Gao C, Hu S et al (2018) Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies. Carcinogenesis 39(2):87–97

pubmed: 29126152

Li L, Wang S, Zhou W (2022) Balance cell apoptosis and pyroptosis of caspase-3-activating chemotherapy for better antitumor therapy. Cancers 15(1):26

pubmed: 36612023 pmcid: 9817729

Liang W, Liu H, Zeng Z, Liang Z, Xie H, Li W et al (2023) KRT17 promotes T-lymphocyte infiltration through the YTHDF2–CXCL10 axis in colorectal cancer. Cancer Immunol Res 11(7):875–894

pubmed: 37129929 pmcid: 10320689

Aslan B, Öğüt T, Erbasan F, Dilbil M, Çelik E, Terzioğlu M et al (2022) The risk of cancer in patients with primary sjögrensyndrome; a single-center study from Turkey. Turk J Med Sci 52(3):587–595

pubmed: 36326315

Goulabchand R, Malafaye N, Jacot W, Viel P, Morel J, Lukas C et al (2021) Cancer incidence in primary sjögren’s syndrome: data from the French hospitalization database. Autoimmun Rev 20(12):102987

pubmed: 34718160

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https://doi.org/10.1186/2046-4053-4-1

Peterson J, Welch V, Losos M, Tugwell PJOOHRI (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hosp Res Inst 2(1):1–12

Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558

pubmed: 12111919

Kang J, Kim H, Kim J, Choi S, Jung S, Jang E et al (2020) Risk of malignancy in Korean patients with primary sjögren’s syndrome. Int J Rheum Dis 23(9):1240–1247

pubmed: 32841507

Mayer M, Martinic M, Reihl-Crnogaj M, Anic B (2023) The risk of developing non-Hodgkin lymphoma and the mortality rate in primary sjögren’s syndrome: a single-centre, retrospective cohort study. Rheumatol Int 43(11):2031–2036

pubmed: 37491526

Isik O, Yazici A, Cefle A (2022) The relationship between malignancy and primary sjogren’s syndrome; single center results. Acta Medica Nicomedia 5(2):49–55

Wang L, Wang W, Lin C, Lin S, Shieh C (2020) Bidirectional relationship between primary sjögren syndrome and non-Hodgkin lymphoma: a nationwide Taiwanese population-based study. J Rheumatol 47(9):1374–1378

pubmed: 31941803

Ahn J, Hwang J, Seo G (2020) Risk of non-Hodgkin’s lymphoma and thyroid cancer in primary Sjögren’s syndrome measured using the Korean Health Insurance Claims Database. Clin Exp Rheumatol 38:40–6

pubmed: 31969226

Brom M, Moyano S, Gandino I, Scolnik M, Soriano E (2019) Incidence of cancer in a cohort of patients with primary sjögren syndrome in Argentina. Rheumatol Int 39(10):1697–1702

pubmed: 31471716

Brito-Zerón P, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón F et al (2017) Characterization and risk estimate of cancer in patients with primary sjögren syndrome. J Hematol Oncol 10(1):90

pubmed: 28416003 pmcid: 5392920

Chiu Y, Chung C, Lin K, Lin C, Chen J, Chen H et al (2017) Predictable biomarkers of developing lymphoma in patients with sjögren syndrome: a nationwide population-based cohort study. Oncotarget 8(30):50098–50108

pubmed: 28177920 pmcid: 5564832

Abrol E, González-Pulido C, Praena-Fernández J, Isenberg D (2014) A retrospective study of long-term outcomes in 152 patients with primary sjögren’s syndrome: 25-year experience. Clin Med 14(2):157–164

Johnsen S, Brun J, Gøransson L, Småstuen M, Johannesen T, Haldorsen K et al (2013) Risk of non-Hodgkin’s lymphoma in primary sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken) 65(5):816–821

pubmed: 23139233

Weng M, Huang Y, Liu M, Lu T (2012) Incidence of cancer in a nationwide population cohort of 7852 patients with primary sjögren’s syndrome in Taiwan. Ann Rheum Dis 71(4):524–527

pubmed: 22072014

Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson L (2006) Lymphoma and other malignancies in primary sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65(6):796–803

pubmed: 16284097

Kauppi M, Pukkala E, Isomäki H (1997) Elevated incidence of hematologic malignancies in patients with sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8(2):201–204

pubmed: 9134244

Liang Y, Yang Z, Qin B, Zhong R (2014) Primary sjögren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73(6):1151–1156

pubmed: 23687261

Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y et al (2022) Primary sjögren’s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev 5:103084

Ekström Smedby K, Vajdic C, Falster M, Engels E, Martínez-Maza O, Turner J et al (2008) Autoimmune disorders and risk of non-hodgkin lymphoma subtypes: a pooled analysis within the interlymph consortium. Blood 111(8):4029–4038

pubmed: 18263783 pmcid: 2288717

Ekström Smedby K, Hjalgrim H, Askling J, Chang E, Gregersen H, Porwit-MacDonald A et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-hodgkin lymphoma by subtype. J Natl Cancer Inst 98(1):51–60

Lazarus M, Robinson D, Mak V, Møller H, Isenberg D (2006) Incidence of cancer in a cohort of patients with primary sjogren’s syndrome. Rheumatology (Oxford) 45(8):1012–1015

pubmed: 16490754

Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J et al (2010) Incidence of malignancy in primary sjögren’s syndrome in a Chinese cohort. Rheumatology (Oxford) 49(3):571–577

pubmed: 20040528

Shi X, Wallach J, Ma X, Rogne T (2024) Autoimmune diseases and risk of non-Hodgkin lymphoma: a Mendelian randomisation study. medRxiv 73(1):17